Anticipation is building for GW Pharmaceuticals (NASDAQ:GWPH) as the biotech prepares to hopefully launch its first product in the U.S. in 2018.
Tag Archives: Biotech
Shares of Insys Therapeutics, a small-cap biotech with a focus on pain management, plunged as much as 30% on Wednesday after receiving a double whammy.
In total, four marijuana stocks jumped higher by at least 10% last week. Let’s take a brief look at some of these moves.
Few stocks have skyrocketed like Axim Biotechnologies. Last year, Axim ranked not only as the best marijuana stock in terms of overall performance, but also took the top spot among all biotech stocks.
There are three different general types of marijuana stocks on the market. Some are marijuana growers. Others provide supplies to marijuana growers. Then there’s the third type: the biotechs. Zynerba Pharmaceuticals belongs to the last kind of marijuana stock.
On June 27, Cara Therapeutics (NASDAQ:CARA), a clinical-stage biotech company with a focus on treating chronic pain and pruritus, surged to an all-time intraday high of $28.50 a share. Cara was just $73 million away from joining the $1 billon market cap ranks.
Shares of Cara Therapeutics Inc., a clinical-stage biotech company with a focus on treating pain and pruritus, rocketed higher by as much as 11% during Wednesday’s trading session after providing an update to its phase 3 trial involving kappa opioid receptor agonist CR845.
In the red-hot world of marijuana stocks, there can be no question that GW Pharmaceuticals reigns supreme, but could small-cap biotech Zogenix be a threat?
Here’s a pot stock that should prove immune to the adverse political winds emanating from the nation’s capital as marijuana is transitioning in the public eye.
A west New York-based biotech company has successfully grown a strain of marijuana that contains zero THC, a feat the company says will transform the medical marijuana industry.
Insys Therapeutics’ stock rose on good news — but not tremendously so.
NEW YORK, March 7, 2017 /Weed Wire/ — Medical Marijuana, Inc. (OTC: MJNA), the first-ever publicly traded cannabis company in the United States, announced today that its major investment company AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM) has enrolled 40 patients and commenced its Phase II clinical trial for the treatment of irritable bowel syndrome (IBS) with the company’s CanChew Plus® CBD gum.
NEW YORK, Jan. 18, 2017 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (OTC: AXIM), a world leader in cannabinoid research and development, has entered clinical trials on treating irritable bowel syndrome (IBS) with the Company’s CanChew Plus® cannabidiol (CBD) gum at Wageningen University in the Netherlands.
NEW YORK, Nov. 16, 2016 /Weed Wire/ — AXIM® Biotechnologies, Inc. (AXIM® Biotech) (AXIM), a world leader in hemp cannabinoid research and development, today announced that the United States Patent and Trademark Office (USPTO) has issued a Notice of Allowance for U.S. Application Serial Number 9,433,601.
SAN DIEGO, June 30, 2015 /Weed Wire/ — Medical Marijuana, Inc. (OTC Pink:MJNA) would like to inform the public and shareholders that it holds 14,943,650 shares of common stock and 500,000 shares of preferred stock in AXIM Biotechnologies(AXIM), a cutting-edge biotechnology innovator.
Consumers who struggle with frequent toothaches now have a cannabis alternative to treat inflammation. AXIM Biotech (OTCQB: AXIM) has introduced Oraximax, the first ever Cannabigerol-based product line.
U.S. Q3 GDP revisions came out today and the news was quite positive. The good old U.S. economy posted a 5% annualized growth rate.